BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Positive Phase 3 Results for Fasedienol Nasal Spray in Social Anxiety Disorder by AffaMed's Partner Vistagen

First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years Statistically significant rapid-onset reducti...

August 11, 2023 | News

Pharming Enrolls First Patient in Japanese APDS Treatment Trial

Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase ...

August 10, 2023 | News

First Patient Dosed in TLX101 Brain Cancer Study for Newly Diagnosed Glioblastoma

IPAX-2 (ClinicalTrials.gov Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with externa...

August 08, 2023 | News

Ascentage Pharma Gets FDA Clearance for Global Phase III Trial of Lisaftoclax in CLL/SLL Patients

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related...

August 07, 2023 | News

Doer Biologics Initiates Phase I MAD Trial of DR10624, Receives NMPA IND Approval

The Phase I MAD study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics ...

August 02, 2023 | News

Chinese Patent Granted for CytoMed Therapeutics' Allogeneic CAR-Gamma Delta T Cell Technology

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its propr...

August 02, 2023 | News

NMPA and FDA Approve First-in-Human Trial for LBL-034 in Multiple Myeloma

This is a first-in-human, single-arm, multicenter, open-label, dose-escalation and expansion clinical study, and plans to enroll patients with relapsed/ref...

August 01, 2023 | News

Everest Medicines Completes Patient Enrollment for Nefecon® China Study

The cOLE study offers an additional 9 months of treatment with Nefecon® to all qualifying patients who have completed the NefIgArd study and will evalu...

August 01, 2023 | News

Daewoong Pharmaceutical Seeks Approval for Fexuprazan in China's Anti-Ulcer Drug Market

Daewoong Pharmaceutical's domestically produced drug no. 34 Fexuprazan, a newly developed one for the treatment of gastroesophageal reflux disease (GERD), ...

July 31, 2023 | News

Transcenta's Anti-sclerostin Antibody TST002 Approved for Phase II Trial in China for Reduced Bone Density Patients

This study aims to evaluate the safety, tolerability, and pharmacokinetics of TST002(Blosozumab) after single and multiple intravenous administrations in p...

July 31, 2023 | News

MSD and Moderna Launch Phase 3 Study for Melanoma Treatment

“As we continue our efforts to advance novel treatment options for patients with high-risk Stage IIB-IV melanoma, the initiation of the V940-001 Phas...

July 28, 2023 | News

GC Genome Enables Prognosis Prediction and Targeted Treatment in Breast Cancer

''We can gain vital insights into patient prognosis and make informed decisions regarding the most effective treatment strategies through ctDNA CNA...

July 27, 2023 | News

Hummingbird Bioscience Advances HMBD-001 Phase IB Trials in Australia, Partners with Omico for Faster Clinical Development

Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung ca...

July 27, 2023 | News

BioMap unveils a “Life Science Leaderboard” to compare AI models

Highlights: New AI leaderboard provides comparison of 25+ of the most important, representative and cutting-edge tasks across six distinct...

July 26, 2023 | News

Stay Connected